Literature DB >> 18022726

The changing epidemiology of hepatitis C virus infection in Europe.

Juan I Esteban1, Silvia Sauleda, Josep Quer.   

Abstract

The epidemic of hepatitis C virus (HCV) infection in Europe is continuously evolving and epidemiological parameters (prevalence, incidence, disease transmission patterns and genotype distribution) have changed substantially during the last 15 years. Four main factors contribute to such changes: increased blood transfusion safety, improvement of healthcare conditions, continuous expansion of intravenous drug use and immigration to Europe from endemic areas. As a result, intravenous drug use has become the main risk factor for HCV transmission, prevalent infections have increased and genotype distribution has changed and diversified. Hence, prevalence data from studies conducted a decade ago may not be useful to estimate the current and future burden of HCV infection and additional epidemiological studies should be conducted, as well as new preventive strategies implemented to control the silent epidemic. This review summarizes recently published data on the epidemiology of HCV infection in Europe focusing on the factors currently shaping the epidemic.

Entities:  

Mesh:

Year:  2007        PMID: 18022726     DOI: 10.1016/j.jhep.2007.07.033

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  121 in total

Review 1.  Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C.

Authors:  Alessio Aghemo; Maria Grazia Rumi; Massimo Colombo
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-07-20       Impact factor: 46.802

2.  Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis.

Authors:  Maja Jovanović; Branislav Jovanović; Milena Potić; Ljiljana Konstantinović; Miodrag Vrbić; Biljana Radovanović-Dinić; Velimir Kostić
Journal:  Bosn J Basic Med Sci       Date:  2010-05       Impact factor: 3.363

3.  High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening.

Authors:  Ennio Polilli; Monica Tontodonati; Maria Elena Flacco; Tamara Ursini; Palmira Striani; Dante Di Giammartino; Maurizio Paoloni; Luigi Vallarola; Gabriella Lucidi Pressanti; Giorgia Fragassi; Patrizia Accorsi; Lamberto Manzoli; Giustino Parruti
Journal:  Infection       Date:  2015-09-12       Impact factor: 3.553

4.  Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Authors:  Andreas Walker; Kathrin Skibbe; Eike Steinmann; Stephanie Pfaender; Thomas Kuntzen; Dominik A Megger; Svenja Groten; Barbara Sitek; Georg M Lauer; Arthur Y Kim; Thomas Pietschmann; Todd M Allen; Joerg Timm
Journal:  J Virol       Date:  2015-10-07       Impact factor: 5.103

Review 5.  Daclatasvir for the Treatment of Chronic Hepatitis C: A Critique of the Clinical and Economic Evidence.

Authors:  Alexis Llewellyn; Rita Faria; Beth Woods; Mark Simmonds; James Lomas; Nerys Woolacott; Susan Griffin
Journal:  Pharmacoeconomics       Date:  2016-10       Impact factor: 4.981

Review 6.  Hepatitis C in hemodialysis patients.

Authors:  Smaragdi Marinaki; John N Boletis; Stratigoula Sakellariou; Ioanna K Delladetsima
Journal:  World J Hepatol       Date:  2015-03-27

7.  HEPATITIS C VIRUS GENOTYPES IN INJECTING DRUG USERS FROM ROMANIA.

Authors:  Camelia Sultana; Codruta Vagu; Aura Temereanca; Camelia Grancea; Josefina Slobozeanu; Simona Ruta
Journal:  Cent Eur J Med       Date:  2011-10

8.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

9.  Injection drug use is a risk factor for HCV infection in urban Egypt.

Authors:  Adela Paez Jimenez; Mostafa K Mohamed; Noha Sharaf Eldin; Hasnaa Abou Seif; Said El Aidi; Yehia Sultan; Nasr Elsaid; Claire Rekacewicz; Mostafa El-Hoseiny; May El-Daly; Mohamed Abdel-Hamid; Arnaud Fontanet
Journal:  PLoS One       Date:  2009-09-28       Impact factor: 3.240

10.  Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection.

Authors:  Maarit Sillanpää; Krister Melén; Päivi Porkka; Riku Fagerlund; Kaisu Nevalainen; Maija Lappalainen; Ilkka Julkunen
Journal:  Virol J       Date:  2009-06-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.